Overall, our observations indicate that monitoring of lipid profiles and hepatic lipid content in RTHβ, possibly focusing particularly on individuals with highly deleterious mutant TRβ genotypes, is warranted, instituting lipid-lowering therapy in patients with hypercholesterolemia and recommending lifestyle changes (such as increased physical activity, weight loss) in individuals with features (eg, central adiposity, hypertriglyceridemia and low HDL-C, insulin resistance) associated with metabolic syndrome. The gene discussed is THRB; the disease is Insulin resistance.